Ergothioneine Blood Pressure Randomized Trial: What the Evidence Says

Quick Answer

Ergothioneine Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• The purpose of the present study was to investigate the association between serum ergothioneine levels and the risk of developing dementia in an older Japanese population. [Meng Xiangyin (2025); evidence level 4]
• Logistic regression for categorical variables and linear regression for continuous variables were used to estimate the age- and sex-adjusted frequencies or mean values of risk factors across the quartiles, respectively. [Meng Xiangyin (2025); evidence level 4]
• This is particularly important for at-risk populations such as Apolipoprotein E ε4 allele carriers, those with a family history of dementia, and those at an early stage of cognitive decline, known as Subjective Cognitive Decline (SCD). [Shan Jiatong (2025); evidence level 4]
• Without early intervention, these at-risk populations groups are likely to progress to dementia. [Shan Jiatong (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For ergothioneine blood pressure randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Meng Xiangyin (2025). Serum ergothioneine and risk of dementia in a general older Japanese population: the Hisayama Study. DOI: 10.1111/pcn.13893. PMCID: PMC12683611. PMID: 40908798. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12683611/
• Shan Jiatong (2025). Study protocol: The efficacy of mushroom to prevent cognitive decline in at-risk middle-aged adults and young-olds living in the community. DOI: 10.3389/fnagi.2025.1588493. PMCID: PMC12183302. PMID: 40552321. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12183302/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.